甲硝唑抗生素治疗可减少小鼠子宫内膜异位症疾病进展:肠道菌群的潜在作用
本研究在小鼠手术诱导的子宫内膜异位症模型中,使用广谱抗生素或甲硝唑治疗,21天后评估病灶体积、重量、增殖与炎症指标及粪便菌群变化。结果显示广谱抗生素使病灶显著缩小约5倍,甲硝唑单独治疗也显著缩小病灶体积,而新霉素无此效果;粪便菌群移植可恢复甲硝唑治疗小鼠的病灶生长和炎症。
要点
- 广谱抗生素治疗使小鼠子宫内膜异位病灶显著缩小约5倍(P < 0.01),增殖细胞减少(P < 0.001)。
- 甲硝唑单独治疗使异位病灶体积显著缩小(P < 0.001),新霉素无此效果。
- 粪便移植可恢复甲硝唑治疗小鼠的病灶生长和炎症(P < 0.05和P < 0.01)。
核心结论
- 抗生素治疗可减少小鼠子宫内膜异位症进展,可能通过减少特定肠道细菌实现。
- 作者认为肠道细菌促进小鼠子宫内膜异位症进展,若转化至人类可能有助于改进诊断工具和个性化治疗策略。
研究设计与样本
- 小鼠接受广谱抗生素或甲硝唑治疗,进行手术诱导的子宫内膜异位症,21天后检测。
- 分析子宫内膜异位病灶的体积、重量和组织学特征,计数Ki-67阳性细胞和Iba1阳性细胞评估增殖和炎症。
- 评估有和无子宫内膜异位症小鼠的粪便细菌组成差异,并进行粪便菌群移植研究。
主要发现
- 广谱抗生素(万古霉素、新霉素、甲硝唑和氨苄青霉素)治疗小鼠的子宫内膜异位病灶显著更小(约5倍;P < 0.01),增殖细胞更少(P < 0.001),较载体治疗小鼠。
- 广谱抗生素治疗小鼠的炎症反应显著降低(P < 0.05),以病灶中巨噬细胞标记Iba1和腹腔液中IL-1β、TNF-α、IL-6和TGF-β1衡量。
- 甲硝唑单独治疗小鼠的异位病灶体积显著更小(P < 0.001),较载体治疗小鼠;新霉素治疗小鼠无此显著差异。
- 甲硝唑治疗小鼠口服灌胃子宫内膜异位症小鼠粪便后,病灶生长和炎症分别恢复(P < 0.05和P < 0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现来自手术诱导的子宫内膜异位症小鼠模型。
- 需进一步研究确定肠道细菌促进炎症的机制、识别促进疾病进展的细菌属或种,并评估这些发现向人类转化的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does altering gut microbiota with antibiotic treatment have any impact on endometriosis progression? SUMMARY ANSWER: Antibiotic therapy reduces endometriosis progression in mice, possibly by reducing specific gut bacteria. WHAT IS KNOWN ALREADY: Endometriosis, a chronic condition causing abdominal pain and infertility, afflicts up to 10% of women between the ages of 25 and 40, ~5 million women in the USA. Current treatment strategies, including hormone therapy and surgery, have significant side effects and do not prevent recurrences. We have little understanding of why some women develop endometriosis and others do not. STUDY DESIGN, SIZE, DURATION: Mice were treated with broad-spectrum antibiotics or metronidazole, subjected to surgically-induced endometriosis and assayed after 21 days. PARTICIPANTS/MATERIALS, SETTING, METHODS: The volumes and weights of endometriotic lesions and histological signatures were analysed. Proliferation and inflammation in lesions were assessed by counting cells that were positive for the proliferation marker Ki-67 and the macrophage marker Iba1, respectively. Differences in faecal bacterial composition were assessed in mice with and without endometriosis, and faecal microbiota transfer studies were performed. MAIN RESULTS AND THE ROLE OF CHANCE: In mice treated with broad-spectrum antibiotics (vancomycin, neomycin, metronidazole and ampicillin), endometriotic lesions were significantly smaller (~ 5-fold; P < 0.01) with fewer proliferating cells (P < 0.001) than those in mice treated with vehicle. Additionally, inflammatory responses, as measured by the macrophage marker Iba1 in lesions and IL-1β, TNF-α, IL-6 and TGF-β1 in peritoneal fluid, were significantly reduced in mice treated with broad-spectrum antibiotics (P < 0.05). In mice treated with metronidazole only, but not in those treated with neomycin, ectopic lesions were significantly (P < 0.001) smaller in volume than those from vehicle-treated mice. Finally, oral gavage of faeces from mice with endometriosis restored the endometriotic lesion growth and inflammation (P < 0.05 and P < 0.01, respectively) in metronidazole-treated mice. LARGE-SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: These findings are from a mouse model of surgically-induced endometriosis. Further studies are needed to determine the mechanism by which gut bacteria promote inflammation, identify bacterial genera or species that promote disease progression and assess the translatability of these findings to humans. WIDER IMPLICATIONS OF THE FINDINGS: Our findings suggest that gut bacteria promote endometriosis progression in mice. This finding if translated to humans, could aid in the development of improved diagnostic tools and personalised treatment strategies. STUDY FUNDING AND COMPETING INTEREST(S): This work was funded, in part, by: a National Institutes of Health (NIH)/ National Institute of Child Health and Human Development (NICHD) grant (R00HD080742) to RK; Washington University School of Medicine start-up funds to RK; an Endometriosis Foundation of America Research Award to R.K.; and an NIH/NICHD grant (R01HD091218) to IUM. The authors report no conflict of interest.
引用
- Chadchan SB, Cheng M, Parnell LA, et al. Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota. Hum Reprod. 2019. PMID: 31037294. doi:10.1093/humrep/dez041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。